Behind routine blood tests and hospital corridors, a new approach to prostate cancer is taking shape, mixing targeted screening, smarter imaging and genetics‑driven treatments that try to help the right men at the right time.
A common cancer that does not always play by the rules
Prostate cancer is now the most frequently diagnosed cancer in men in many Western countries, especially after the age of 50. Yet it behaves in strikingly different ways from one patient to another.
In a large number of cases, the tumour grows so slowly that it may never cause symptoms or threaten life. In others, it turns aggressive, spreads to bones and lymph nodes, and becomes much harder to control.
Older adults keep habits younger people mock, yet psychologists say they reduce mental overload
Doctors are moving away from “treat everything, treat early” and towards “treat precisely, when the patient will truly benefit”.
The tumour starts in the prostate, a walnut‑sized gland that sits just below the bladder and surrounds part of the urethra. The most frequent form is called adenocarcinoma. Early phases are usually symptom‑free.
When signs do appear, they tend to be late: trouble urinating, a weaker stream, frequent night‑time trips to the toilet, or bone pain when metastases settle in the skeleton. Fatigue and weight loss can also hint that the disease has advanced.
For years, screening relied on two basic tools: a blood test called PSA (prostate‑specific antigen) and a rectal examination to feel the gland. Both have limits. PSA can rise for many reasons, including benign conditions or infections. A normal PSA does not completely rule out cancer either.
From blanket screening to targeted checks
Large countries, including France and the UK, have resisted universal prostate cancer screening for all men. Data suggest that mass testing does not clearly cut deaths enough to justify side effects such as overdiagnosis and overtreatment.
That does not mean ignoring the disease. It means being more selective.
The current trend is towards risk‑based screening: start with those most likely to benefit, and spare others from unnecessary tests.
For most healthy men with no family history and no urinary symptoms, an annual PSA from midlife is no longer seen as an automatic step. Instead, doctors consider age, life expectancy and personal risk factors before ordering tests.
Who may be advised to get tested?
- Men between 50 and 70 whose life expectancy is above ten years
- Men from around 45 with a strong family history of prostate, breast or ovarian cancer
- Men carrying high‑risk mutations, such as BRCA1 or BRCA2
- Patients with persistent urinary symptoms or unexplained pain
If PSA is elevated or the rectal exam feels abnormal, the next step in 2025 is rarely a direct jump to biopsies. Instead, urologists increasingly order a multiparametric MRI of the prostate. This detailed imaging scan helps spot suspicious areas and guide where, and whether, tissue samples are really needed.
This sequence – PSA, then MRI, then targeted biopsies if required – cuts the number of unnecessary biopsies and reduces the risk of finding tiny, harmless cancers that would never have caused trouble.
New blood tests are also appearing on the market, including PHI (Prostate Health Index) and 4Kscore. These tests combine several markers to refine the estimate of a man’s risk and support shared decision‑making between patient and clinician.
Treatment: less intensity for some, more precision for others
The toolbox for prostate cancer has not disappeared: surgery, radiotherapy and hormone therapy remain the backbone of treatment. What is changing is when and how they are used.
For men with small, low‑risk tumours, “active surveillance” has become common. Instead of rushing to surgery or radiation, doctors monitor PSA levels, perform repeat scans and sometimes new biopsies. Curative treatment is only started if the cancer shows signs of picking up speed.
Avoiding heavy treatment for low‑risk disease protects continence, erection and day‑to‑day quality of life without sacrificing survival in carefully selected men.
For intermediate‑ and high‑risk cancers, clinicians increasingly combine radiotherapy with hormone therapy that suppresses testosterone, the hormone that fuels many prostate tumours. Newer anti‑androgen pills, such as enzalutamide, have shown strong activity, especially when the cancer recurs without visible metastases but the PSA is doubling quickly.
Regulators like the US Food and Drug Administration have already approved some of these combinations in specific settings. Oncologists remain cautious though, balancing survival gains against fatigue, hot flushes, metabolic changes and sexual side effects.
Imaging that tracks tumours almost in real time
A quieter revolution is happening in nuclear medicine labs. One emerging technique, whole‑body SPECT, offers a 3D view of the entire skeleton and can detect very small bone metastases that traditional scans miss.
In recent research, this high‑sensitivity scintigraphy has been able to track changes in bone lesions over days rather than months.
| Technique | Main use | Key advantage |
|---|---|---|
| Multiparametric MRI | Local prostate imaging | Fewer unnecessary biopsies, better targeting |
| Whole‑body SPECT | Bone metastasis monitoring | Detects micro‑metastases and tracks their evolution |
With this kind of detailed map, oncologists can adapt treatment more quickly – escalating when new spots appear, or sparing patients from extra cycles when disease stays stable.
Research labs chase the resistant forms
As therapies improve, a growing challenge is resistance. Many advanced prostate cancers eventually escape standard hormone treatments. Researchers are now digging into tumour biology to understand how and to find new vulnerabilities.
One intriguing target is a thyroid hormone receptor called TRβ. Laboratory studies suggest this receptor can act like a tumour brake. When activated, it may slow cell division and restore sensitivity to anti‑androgen drugs while boosting the effect of radiotherapy.
Multiple experimental projects are looking at combinations such as TRβ activators plus enzalutamide to beat back resistant disease.
Gene editing tools like CRISPR‑Cas9 are also being used in preclinical models. Scientists have identified a “chaperone” protein, PTGES3, that helps switch on the androgen receptor, a key driver of prostate cancer growth.
Switching off PTGES3 in the lab appears to make cancer cells more vulnerable to hormone therapy and radiation. These techniques remain far from day‑to‑day clinics, but they offer clues that could inspire new drugs.
Other strategies focus on DNA repair. Many aggressive prostate tumours carry defects in genes such as BRCA1, BRCA2 or ATM, which normally help repair damaged DNA. Drugs called PARP inhibitors block an alternative repair route and can push such cancer cells over the edge.
Trials are testing these agents alone and in combination with radiotherapy or hormonal agents. Early signals show particular benefit in men whose tumours harbour DNA repair mutations, though some benefit may extend beyond that group.
Precision medicine slowly becomes reality
All these developments feed into a broader shift: viewing prostate cancer not as one disease, but as a group of related illnesses with distinct genetic and molecular fingerprints.
In advanced or metastatic stages, doctors now increasingly send tumour samples – or sometimes blood samples containing circulating tumour DNA – for genomic sequencing. The goal is to spot actionable mutations and match patients to targeted therapies or clinical trials.
The long‑term ambition is clear: one patient, one tumour profile, one tailored treatment plan.
In practice, this means that two men with similar PSA levels and scan results might receive quite different treatments because their tumour genetics do not match. Access to this kind of care still varies widely by country, region and hospital budget.
What patients and families should know
For anyone facing a new diagnosis, the range of options can feel overwhelming. A few points often help structure the conversation with the medical team:
- Ask about your risk category: low, intermediate, high, or metastatic
- Check whether active surveillance is a safe option in your case
- Discuss potential side effects of each treatment, especially for continence and sexual function
- Ask if genomic testing is relevant and available for your stage of disease
- Consider a second opinion in complex or advanced cases
Some men also look at lifestyle measures alongside medical treatment. While diet or supplements cannot cure cancer, regular exercise, weight control and stopping smoking can support general health and may improve tolerance to therapies. Antioxidants and plant extracts, often marketed online, need careful discussion with a doctor, as some can interfere with prescribed drugs or radiotherapy.
One practical scenario often raised is the 65‑year‑old man with a slow‑growing tumour and other health problems such as heart disease or diabetes. In such a case, an aggressive operation might carry more risk than benefit. Active surveillance or gentle radiotherapy could make more sense. By contrast, a fit 55‑year‑old with high‑risk disease might be offered a combination of radiation, hormone therapy and, in future, a targeted drug based on his tumour’s mutations.
Behind these choices sits a simple trend: prostate cancer care is becoming less about one‑size‑fits‑all guidelines and more about tailored strategies built on risk, imaging, biology and life goals. As genetic tools, artificial intelligence and advanced scans gradually spread, that shift is likely to accelerate, reshaping how men live with – and beyond – this complex disease.
